Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
Subscribe to see CLEVER CULTURE SYSTEMS LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CLEVER CULTURE SYSTEMS LIMITED is a health care equipment & services company headquartered in Adelaide, Australia. It is publicly listed (CC5) with a market capitalisation of $21.7M. Xcout tracks 5 named people at CLEVER CULTURE SYSTEMS LIMITED, including Brent Barnes (Chief Executive Officer and Managing Director).
A few of CLEVER CULTURE SYSTEMS LIMITED's closest competitors — see the full list of competitors and alternatives →
Pictura Bio is a medical technology company developing a one-minute pathogen detection platform utilizing proprietary hardware and computer vision for infectious disease diagnostics. Its point-of-care system, which includes the PIC-ID and VISTA reader technologies, provides rapid identification and differentiation of pathogens to assist frontline healthcare providers.
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
BlinkLab Limited, founded by neuroscientists, has developed a smartphone-based diagnostic platform for neurodevelopmental conditions like autism and ADHD. The technology uses AI and machine learning for screening tests in children as young as 18 months, aiming for earlier detection and intervention. The company is pursuing FDA approval to facilitate broader use of its technology.
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
CellaVision provides digital hematology microscopy solutions, including hardware analyzers, instruments, reagents, and specialized software applications. The company automates and streamlines workflows for human and veterinary laboratories of all sizes to analyze blood and body fluid samples.
AVE Science&Technology CO.,LTD operates comprehensively in the medical technology sector, engaging in the full spectrum of activities from initial research and development to manufacturing, sales, and post-sale support. Its diverse portfolio includes medical devices, biological reagents, remote medical diagnostic networks, specialized computer software, automated control systems, and various medical auxiliary equipment. The company's product offerings prominently feature advanced diagnostic instruments, such as analyzers for urine formed elements (along with their associated reagents), automated urine analysis systems, multi-functional microscopy devices, semi-automatic biochemical analyzers, and feces analyzers. Complementing these devices, AVE Science&Technology also supplies essential consumables, including reagent kits, quality control solutions for analyzers, test strips, and cleaning agents. Serving a global clientele, the company's reach extends across Europe, the United States, Asia, and Africa. Established in 2000, AVE Science&Technology CO.,LTD is headquartered in Changsha, China. The organization transitioned to its present name in September 2012, having previously been known as Changsha High - tech Industrial Development Zone Aiwei Technology Industrial Co., Ltd.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.